- New journal section will focus on emerging and translation work in the field of regenerative medicine - MELVILLE, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, is pleased to announce that its Chief Scientist and Vice President of Research and Development, Francisco Silva, has been named Section Editor of the newly launched Regenerative Medicine section of the J ...

– Adds to comprehensive patent portfolio underlying novel ThermoStem® technology platform – – Expanding intellectual property estate expected to help drive ThermoStem® licensing opportunities – – Substantive discussions continue with commercial stage regenerative medicine company with regard to a license of ThermoStem® IP – MELVILLE, N.Y., June 27, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell ...

- Significant YoY improvement in operating performance - - Ends Q1-2024 with $16.4 million cash, cash equivalents, and marketable securities - MELVILLE, N.Y., June 17, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, announced that it has received notice from the Nasdaq Stock Market that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) in connection with the filing o ...

- Brown adipose derived stem cells with brown adipogenic potential would represent a new modality for the treatment of obesity and related metabolic disorders – - ThermoStem® is an off-the-shelf platform, well-protected by a comprehensive portfolio of issued patents that cover both the U.S. and international markets – - Potential license partner is a leading commercial stage regenerative medicine company – MELVILLE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "B ...

- Brown adipose derived stem cells with brown adipogenic potential would represent a new modality for the treatment of obesity and related metabolic disorders – - ThermoStem® is an off-the-shelf platform, well-protected by a comprehensive portfolio of issued patents that cover both the U.S. and international markets – - Potential license partner is a leading commercial stage regenerative medicine company – MELVILLE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “B ...

Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $1.53 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -3.92%. A quarter ago, it was expected that this company would post a loss of $0.65 per share when it actually produced a loss of $0.57, delivering a surprise of 12.31%.Over the last four quarters, the compa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _________ Commission file number: 001-37603 BIORESTORATIVE THERAPIES, INC. (Exact name of registrant as specified in its charter) Nevada 30-1341024 (State o ...

MELVILLE, NY., June 04, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company" or "BioRestorative") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jefferies Global Healthcare Conference being held June 5-6, 2024 at the Marriot Marquis in New York. Management will also be available for one-on-one investor meetings during the conference. About BioRestorative Therapies, Inc. BioRestorative Therapies, I ...

MELVILLE, NY., June 04, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company" or "BioRestorative") (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jefferies Global Healthcare Conference being held June 5-6, 2024 at the Marriot Marquis in New York. Management will also be available for one-on-one investor meetings during the conference. About BioRestorative Therapies, Inc. BioRestorative Therapies, ...

财务数据和关键指标变化 - 公司于2024年3月31日的现金、现金等价物和有价证券为1640万美元 [34] 各条业务线数据和关键指标变化 - 公司的BRTX-100细胞治疗候选药物正在进行II期临床试验,初步26周和52周的盲态数据显示了积极的趋势,未出现严重不良事件 [16][17] - 公司的ThermoStem平台开发了一种针对肥胖的新型外泌体生物制品,计划于2024年第三季度提交IND申请,并在年内启动首次人体临床试验 [22][24] - 公司与Cartessa公司签署了为期5年的独家协议,将向其供应公司自主研发的细胞生物制品商业产品,用于美容领域 [27][28][29] 各个市场数据和关键指标变化 - 公司正在积极探索将管线产品商业化,并已开始与一些国家进行初步合作和许可谈判 [24] 公司战略和发展方向及行业竞争 - 公司正在积极推进BRTX-100的II期临床试验,并已获得FDA批准对对照组的注射方式进行修改,以提高试验结果的可靠性 [17][19][20] - 公司正在开发一种针对肥胖的新型外泌体生物制品,作为现有减肥药物的辅助疗法,有望降低其副作用 [40][41][45] - 公司与Cartessa的合作有助于建立强大的商业引擎,为公司的研发项目提供资金支持 [27][28][34] 管理层对经营环境和未来前景的评论 - 公司管理层对BRTX-100和ThermoStem项目的未来前景表示乐观,认为这些项目都有重大的价值增值催化剂 [27][33][34] - 公司管理层认为与Cartessa的合作将为公司带来可观的收入和现金流,有助于减少对资本市场的依赖 [57] 问答环节重要的提问和回答 问题1 **Michael Okunewitch 提问** 询问公司使用外泌体产品相比细胞治疗在肥胖治疗中的优势 [39] **Lance Alstodt 和 Francisco Silva 回答** 外泌体产品不需要植入,不会引起免疫排斥反应,制造成本也更低,且从监管角度可能更简单 [40][41][42][43] 问题2 **Jonathan Aschoff 提问** 询问Northwell医疗中心在II期临床试验中的作用 [58][59][64][65] **Lance Alstodt 回答** Northwell医疗中心是16个试验中心之一,但在患者招募方面表现出色,公司正在为其提供支持 [59][64][65] 问题3 **Jonathan Aschoff 提问** 询问公司是否能依靠美容业务的最低采购量为II期临床试验提供资金支持 [56][57] **Robert Kristal 回答** 美容业务的收入和毛利率都很可观,但不足以完全支持II期临床试验,公司仍需要依赖资本市场 [57]